Laureate Pharma Sponsors Live Webcast on Development of a Third-Generation Antibody for Therapy of Prostate Cancer

Strategic Insights -

Laureate Pharma, a biopharmaceutical development and protein production company, is sponsoring a live webcast on the development of a third-generation antibody for therapy of prostate cancer. The webcast, presented by BioPharm International, will feature presentations by experts from Cytogen Corporation, Laureate Pharma, and Memorial Sloan Kettering Cancer Center. The experts will discuss the development of radiolabeled therapeutic antibodies and the challenges associated with their production and clinical trials.

Key Takeaways:

  • The development of radiolabeled therapeutic antibodies is a complex process involving the selection of an isotope with optimal radiation properties and secure mechanisms of isotope attachment.
  • Such antibodies have enhanced potency in cancer therapy, directing radiation to specific areas of disease, and are expected to play a significant role in cancer treatment.
  • The development of a new radiolabeled antibody therapeutic, combining a PSMA-specific targeting antibody with a high-affinity chelator and a beta-emitting isotope, has overcome challenges and will enter clinical trials next month.
  • The webcast will focus on the critical decisions made along the development path, including the selection of the targeting antibody, the rational choice of radioisotope, and the design and properties of chelators for optimal attachment of radio-metallic isotopes to antibodies.
  • The multi-company collaboration between Cytogen and Laureate Pharma has enabled the successful development of a complex radiolabeled biopharmaceutical.
  • The webcast will also address the value of radiolabeled antibodies in cancer therapy and the logistical challenges associated with their production and clinical trials.

Statistics:

  • The webcast is scheduled to take place on June 8 at 2PM EDT.
  • Over 100 scientists, researchers, and industry experts are expected to participate in the live Q&A session during the conclusion of the webcast.
  • The development of the new radiolabeled antibody therapeutic is expected to begin clinical trials next month.
  • The partnership between Cytogen and Laureate Pharma has accelerated the development of new biopharmaceuticals, leveraging the strengths of each company.

Sources:

  • Laureate Pharma's press release, "Laureate Pharma Sponsors Live Webcast on Development of a Third-Generation Antibody for Therapy of Prostate Cancer" (June 1).
  • BioPharm International website, "RadioLabels" (2007).
  • Laureate Pharma website, http://www.laureatepharma.com.
  • Safeguard Scientifics website, http://www.safeguard.com.